Table 7.
Mortality-related outcome data from studies of cancer patients treated with irinotecan, stratified by UGT1A1 genotype
| Study | Outcome measure | Finding |
|---|---|---|
| Font et al.44 | Time to progression | 3 mo (*1/*1) vs. 4 mo (othera) |
| Median survival | 8 mo (*1/*1) vs. 11 mo (other) | |
| 1 yr survival | 21% (*1/*1) vs. 41% (other) | |
| 2 yr survival | 14% (*1/*1) vs. 31% (other) | |
| Marcuello et al.46 | Median survival | 32 mo (*1/*1) vs. 24 mo (other1) |
| Toffoli et al.56 | Hazard ratio | 0.81 (95% CI 0.45–1.44) (*28/*28 vs. *1/*1) |
| Hazard ratio | 0.84 (95% CI 0.58–1.21) (*1/*28 vs. *1/*1) | |
| Median survival | 613 days (*1/*1) vs. 686 days (*28/*28) | |
| Median survival | 613 days (*1/*1) vs. 669 days (*1/*28) |
a
Other includes both heterozygotes (*1/*28) and homozygotes (*28/*28).